Literature DB >> 21297267

Berberine attenuates calyculin A-induced cytotoxicity and Tau hyperphosphorylation in HEK293 cells.

Guang Yu1, Yi Li, Qing Tian, Rong Liu, Qun Wang, Jian-Zhi Wang, Xiaochuan Wang.   

Abstract

The Chinese herb berberine has versatile health effects. Recent reports indicate that berberine has the potential to prevent and treat Alzheimer's disease (AD). In the present study, we employed tau-expressing HEK293 cells (HEK293/tau) treated with calyculin-A as a cellular model to investigate the roles of berberine in cell viability, tau phosphorylation, and oxidative stress. We found a significant reduction of calyculin A-induced tau hyperphosphorylation at Ser198/199/202, Ser396, Ser404, Thr205, and Thr231 24 h after treatment with 20 μg/ml berberine. Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3β (GSK-3β) activation, as determined by phosphatase activity assay and GSK-3β phosphorylation at Tyr216 and Ser9, respectively. Furthermore, berberine reversed both the increase of malondialdehyde and the decrease of superoxide dismutase activity induced by calyculin A, indicating its role in anti-oxidative stress. Our findings suggest that berberine may be a potential therapeutic drug for AD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21297267     DOI: 10.3233/JAD-2011-101779

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  13 in total

1.  Glycoside hydrolase family 18 and 20 enzymes are novel targets of the traditional medicine berberine.

Authors:  Yanwei Duan; Tian Liu; Yong Zhou; Tongyi Dou; Qing Yang
Journal:  J Biol Chem       Date:  2018-08-22       Impact factor: 5.157

2.  Human tau may modify glucocorticoids-mediated regulation of cAMP-dependent kinase and phosphorylated cAMP response element binding protein.

Authors:  Yudong Liu; Ying Su; Shenggang Sun; Tao Wang; Xian Qiao; Hui Li; Xiaoqin Run; Zhihou Liang
Journal:  Neurochem Res       Date:  2012-05       Impact factor: 3.996

Review 3.  History in Perspective: The prime pathological players and role of phytochemicals in Alzheimer's disease.

Authors:  Mohd Sajad; Rajesh Kumar; Sonu Chand Thakur
Journal:  IBRO Neurosci Rep       Date:  2022-04-28

4.  Decrease in the production of β-amyloid by berberine inhibition of the expression of β-secretase in HEK293 cells.

Authors:  Feiqi Zhu; Fujun Wu; Ying Ma; Guangjian Liu; Zhong Li; Yong'an Sun; Zhong Pei
Journal:  BMC Neurosci       Date:  2011-12-12       Impact factor: 3.288

5.  Tau phosphorylation and μ-calpain activation mediate the dexamethasone-induced inhibition on the insulin-stimulated Akt phosphorylation.

Authors:  Yudong Liu; Ying Su; Shenggang Sun; Tao Wang; Xian Qiao; Xiaoqin Run; Zhihou Liang
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

6.  Natural products as promising drug candidates for the treatment of Alzheimer's disease: molecular mechanism aspect.

Authors:  Niloufar Ansari; Fariba Khodagholi
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

7.  Berberine attenuates axonal transport impairment and axonopathy induced by Calyculin A in N2a cells.

Authors:  Xiaofeng Liu; Jie Zhou; Morad Dirhem Naji Abid; Huanhuan Yan; Hao Huang; Limin Wan; Zuohua Feng; Juan Chen
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

8.  Fuzheng Quxie Decoction Ameliorates Learning and Memory Impairment in SAMP8 Mice by Decreasing Tau Hyperphosphorylation.

Authors:  Yang Yang; Xingxing Jia; Jianchao Feng; Zhiyong Wang; Yu Cao; Jiangang Liu; Hao Li
Journal:  Evid Based Complement Alternat Med       Date:  2017-12-20       Impact factor: 2.629

9.  The total alkaloids from Coptis chinensis Franch improve cognitive deficits in type 2 diabetic rats.

Authors:  Jia-Chuan Li; Xiao-Fei Shen; Jun-Ao Shao; Meng-Min Tao; Jian Gu; Jingyu Li; Ning Huang
Journal:  Drug Des Devel Ther       Date:  2018-08-31       Impact factor: 4.162

Review 10.  Role of berberine in Alzheimer's disease.

Authors:  Zhiyou Cai; Chuanling Wang; Wenming Yang
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-03       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.